CE marked,
ISO 15189:2022 Medical Laboratories
90%+ Accuracy
Prediction accuracy, PPV & NPV
against clinical outcomes
All Solid Tumors
Applicable to
all solid tumors
All Therapy Classes
Applicable to all therapy
classes and combinations
CE marking confirms cResponse™ meets EU requirements for safety, health, and performance as an in vitro diagnostic device. ISO 15189:2022 accreditation of our medical laboratories in the UK and Israel confirms the laboratory processes behind it meet the international standard for medical laboratory quality and competence.
What makes it human biology, not a model
What sets the platform apart: the tissue tested is human, not an AI simulation or an animal model; it's living tissue, not disaggregated or reconstructed; the tumor microenvironment around it stays intact; and it's kept that way for long enough to see real drug effects, not just an initial reading.
The complete tumor microenvironment, intact
The tumor microenvironment (TME), stromal cells, immune infiltrate, vasculature, and extracellular matrix, is maintained fully intact. No disaggregation, no expansion, no murine substitution. The tissue tested is the patient's own living biology, not a model of it.
Most ex-vivo platforms destroy the TME in the process of preparing tissue for testing. cResponse™ preserves it, maintaining the exact biological context that drives real drug response and resistance, for 7+ days of standard functional testing. Some agents require longer exposure to reach maximum effect; tissue structure and viability have been demonstrated in extended culture out to 20 days.
Up to 8 agents, chemotherapy, targeted agents, immunotherapy, antibody-drug conjugates, and combinations, are tested simultaneously on the same tissue sample. Every agent is measured against the same biological baseline, producing a direct comparative ranking rather than isolated measurements.
The result is a direct measurement of which treatments affect that patient's own tissue, not a prediction model built on population data or a genomic proxy.
The clinical report delivered to the oncologist ranks every tested drug by functional score, summarizes the genomic findings from the sequencing panel where used, and includes tissue images from the testing itself.
From biopsy to ranked treatment matrix
A two-week process, six phases, from tissue collection to the report delivered to the oncologist.
1
Day 0 · collection, QA & sectioning
Biopsy collected, quality-checked, and sectioned
A standard core needle biopsy is collected from the patient's tumor. For pharma projects, tissue is sourced from resected specimens or biobank material provided by the partner. Our courier meets the clinical team at the procedure room and delivers it to a regional cResponse™ service center the same day, no additional procedure beyond what's already planned. There, the sample passes quality-assurance testing and is sectioned into thick slices, ready for parallel processing.
→ QA-passed, sectioned tissue ready for parallel processing2
Day 1 · panel selection · optional
Rapid genomic sequencing surfaces candidate drugs
The oncologist provides the initial list of drugs to test. For pharma partners, the candidate compounds are provided by the customer. Optionally, part of the sectioned sample undergoes rapid genomic sequencing across 58 of the most actionable genes*, identifying tumor-specific mutations that may be targeted by specific therapies. Any promising candidates this surfaces are added to the panel alongside the physician's or partner's own selections, not used as a predictive biomarker in itself.
→ Final panel of candidate therapies3
Days 2–9 · culture & treatment
Up to 8 treatments tested in native tissue
Sections are placed in a proprietary assay culture matrix that keeps the tumor tissue alive and responsive with its own microenvironment intact, immune cells, stromal cells, vasculature, and extracellular matrix, for 7+ days of standard testing (up to 20 days demonstrated in extended culture). The full panel, chemotherapy, targeted agents, immunotherapy, ADCs, and combinations, is applied under CURESPONSE's proprietary treatment conditions, every agent measured against the same biological baseline.
→ Multi-dimensional functional response, in progress4
Days 10–12 · pathology & algorithm
Pathologist scoring and the cResponse™ score
Tissue response, cell death, drug damage, and structural change, is digitized and evaluated by expert pathologists alongside AI-assisted image analysis. A proprietary algorithm then converts that pathologist-scored, AI-processed readout into a single cResponse™ score per drug, prioritizing every tested option by demonstrated efficacy on that patient's own tissue.
→ Ranked cResponse™ score, per drug5
~Day 14 · report
Ranked treatment report delivered to the oncologist
The final report, ranked drug scores, the genomic summary where sequencing was used, and supporting tissue images, is issued to the treating oncologist, indicating the options with the strongest response while helping avoid unnecessary use of ineffective drugs.
→ Report in the oncologist's handslogistics included
Our courier waits outside the procedure room, transfers tissue to our proprietary medium and cooling box, and ships to the lab under controlled conditions. One call to book, we handle the rest.
* Rapid genome sequencing NGS panel, covering 58 genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, ERBB2, ERBB4, ESR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MPL, MSH6, NOTCH1, NMP1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, TSC1, TSC2, VHL.
A decade of proprietary process refinement
Every step above depends on hundreds of tightly controlled variables. Three categories of proprietary protocol are what turn a biopsy into a reliable result.
I
Ensuring accurate & comprehensive ex-vivo/in-vitro functional mirroring
TME handlingGasesSlicingRotationMatrixScaffoldMediumLocationOrdering of slicesTemperatureIncubationProtocols
II
Ensuring accurate, broad coverage of ex-vivo/in-vitro therapy dynamics
DosingCalibrationsTreatment protocolProfilingDerivativesTimingThresholdsCombinations
III
Ensuring consistent, high-resolution analytics & results
LocationPre-processingDrug damageScoring algorithmsTissue damageHuman pathologyAI image analysis
Evidence
Publications, posters, and validation studies backing the platform.
Publications & posters
Peer-reviewed · J Pers Med · 2026
Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment
Bar V, et al. J. Pers. Med. 2026, 16, 298. A 278-report post-market study showing 91.18% PPV and 90.91% NPV, with at least one effective treatment identified for 83.7% of patients overall.
Read more →Poster · MAP Congress 2023
A phase 2 clinical trial of cResponse, a functional assay for cancer precision medicine
Presented at the 2023 Molecular Analysis for Precision Oncology Congress.
Download poster →Peer-reviewed · 2023
A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy
Golan S, Bar V, Salpeter SJ, et al. Front. Med. 2023, 10, 1221484. The multicenter prospective trial establishing 96% sensitivity and 77.7% specificity that the 2026 study above confirms.
Read more →Cancer Discovery · 2023
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer
Stossel C, Berger R, Golan T, et al. Cancer Discov. 2023, 13, 1–18. Uses cResponse™ to correlate ex vivo sensitivity with clinical outcomes in BRCA-associated pancreatic cancer.
Read more →Poster · AACR 2023
A phase 2 clinical trial of cResponse, a functional assay for cancer precision medicine
Presented at the American Association for Cancer Research Annual Meeting, April 2023.
Download poster →Poster · ESMO IO 2022
Using the cResponse Technology to Evaluate a T-Cell Bispecific CEACAM5 Therapy
Presented at the 2022 ESMO Immuno-Oncology Congress.
Download poster →Nature Cancer · 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer
Gavert N, Zwang Y, Weiser R, et al. Nat. Cancer 2022, 3, 219–231. The foundational platform paper behind the MEK-Src combination now under U.S. patent allowance.
Read more →Poster · SABCS 2021
Evaluating an Ex Vivo Organ Culture (EVOC) System for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer
Gal-Yam EN, Sklair-Levi M, Salpeter S, et al. San Antonio Breast Cancer Symposium, December 2021, with Sheba Medical Center. In a 15-patient pre-neoadjuvant breast cancer cohort, cResponse™ scores showed high concordance with pathological complete response and residual cancer burden (RCB) class, supporting feasibility as a predictive tool for neoadjuvant chemotherapy selection.
Poster · AACR 2021
A clinical trial of cResponse, a functional assay for cancer precision medicine
Salpeter S, Stossel C, Bar V, et al. AACR Annual Meeting 2021, with Weizmann Institute, Sheba, Rabin, Kaplan, and Hadassah Medical Centers. Across 65 patient samples spanning bladder, pancreatic, lung, colorectal, breast, and sarcoma cancers, cResponse™ demonstrated 87% specificity (33/38) and 96% sensitivity (25/27) against clinical outcome, alongside >90% tissue viability sustained over 7 days across 20+ tumor types.
Related research from CURESPONSE's founding science
Want to learn more about CURESPONSE?